Published in Mol Imaging on October 01, 2003
Ovarian cancer. Annu Rev Pathol (2009) 4.92
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell (2013) 4.58
Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature (2013) 3.39
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A (2005) 2.54
Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J (2009) 2.31
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol (2012) 1.87
Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood (2012) 1.64
Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol (2009) 1.59
ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell (2007) 1.53
Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology (2009) 1.31
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med (2013) 1.30
A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A (2012) 1.23
A synthetic luciferin improves bioluminescence imaging in live mice. Nat Methods (2014) 1.23
Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med (2014) 1.22
Toxoplasma secreting Cre recombinase for analysis of host-parasite interactions. Nat Methods (2010) 1.20
Quantification of factors influencing fluorescent protein expression using RMCE to generate an allelic series in the ROSA26 locus in mice. Dis Model Mech (2011) 1.16
Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res (2011) 1.07
Generation of a highly inducible Gal4-->Fluc universal reporter mouse for in vivo bioluminescence imaging. Proc Natl Acad Sci U S A (2008) 1.04
A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol (2006) 1.03
Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. Proc Natl Acad Sci U S A (2014) 1.02
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol (2011) 1.01
Strict control of transgene expression in a mouse model for sensitive biological applications based on RMCE compatible ES cells. Nucleic Acids Res (2010) 1.00
Hepatitis C virus infection and related liver disease: the quest for the best animal model. Front Microbiol (2013) 0.99
Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice. BMC Biotechnol (2009) 0.98
Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. Mol Ther (2010) 0.96
Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer. Sci Signal (2015) 0.93
SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget (2015) 0.92
Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. Mol Ther (2008) 0.91
Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo. Cancer Discov (2013) 0.89
A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. Proc Natl Acad Sci U S A (2009) 0.89
Study of hepatitis C virus entry in genetically humanized mice. Methods (2012) 0.85
Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol (2013) 0.84
Synthesis of a pH-sensitive nitrilotriacetic linker to peptide transduction domains to enable intracellular delivery of histidine imidazole ring-containing macromolecules. J Am Chem Soc (2010) 0.82
Visualizing hepatitis C virus infection in humanized mice. J Immunol Methods (2014) 0.82
A vector-host system to fingerprint virus tropism. Hum Gene Ther (2012) 0.81
Cancer Stem Cell Marker Phenotypes Are Reversible and Functionally Homogeneous in a Preclinical Model of Pancreatic Cancer. Cancer Res (2015) 0.79
Vulnerability of the developing heart to oxygen deprivation as a cause of congenital heart defects. J Am Heart Assoc (2014) 0.79
Transcriptional targeting in the airway using novel gene regulatory elements. Am J Respir Cell Mol Biol (2012) 0.78
Conditional bicistronic Cre reporter line expressing both firefly luciferase and β-galactosidase. Mol Imaging Biol (2011) 0.76
Tissue-Specific Regulation of Oncogene Expression Using Cre-Inducible ROSA26 Knock-In Transgenic Mice. Curr Protoc Mouse Biol (2015) 0.76
Systemic injection of AAV9 carrying a periostin promoter targets gene expression to a myofibroblast-like lineage in mouse hearts after reperfused myocardial infarction. Gene Ther (2016) 0.75
Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. MBio (2016) 0.75
Mice expressing minimally humanized CD81 and occludin genes support hepatitis C virus uptake in vivo. J Virol (2016) 0.75
Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. JCI Insight (2017) 0.75
Non-Invasive Quantification of Cartilage Using a Novel In Vivo Bioluminescent Reporter Mouse. PLoS One (2015) 0.75
Ontogeny and localization of the cells produce IL-2 in healthy animals. Cytokine (2013) 0.75
Efficient Generation of Mice with Consistent Transgene Expression by FEEST. Sci Rep (2015) 0.75
Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression. Cell Rep (2017) 0.75
ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas. Cancer Res (2017) 0.75
A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging. PLoS One (2017) 0.75
Selective inhibition of BET bromodomains. Nature (2010) 18.79
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37
Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature (2010) 4.36
Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science (2003) 4.32
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell (2003) 4.13
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A (2002) 4.03
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science (2002) 3.86
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature (2004) 3.63
Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell (2005) 3.51
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47
Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov (2011) 3.45
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A (2002) 3.28
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science (2003) 3.21
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A (2009) 2.95
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol (2008) 2.93
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol (2008) 2.75
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol (2006) 2.60
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A (2005) 2.54
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood (2007) 2.51
The requirement for cyclin D function in tumor maintenance. Cancer Cell (2012) 2.49
A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell (2010) 2.47
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A (2014) 2.46
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J (2006) 2.41
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood (2012) 2.35
Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell (2005) 2.35
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 2.31
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A (2008) 2.27
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nat Struct Biol (2003) 2.23
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res (2010) 2.20
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A (2006) 2.17
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest (2012) 2.17
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell (2009) 2.15
Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A (2009) 2.08
VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol (2006) 2.03
Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci U S A (2002) 2.03
Regulation of endocytosis via the oxygen-sensing pathway. Nat Med (2009) 2.00
HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest (2003) 1.99
Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A (2002) 1.99
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell (2004) 1.98
Q&A: Cancer: clues from cell metabolism. Nature (2010) 1.98
Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell (2010) 1.95
Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell (2012) 1.93
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol (2007) 1.92
The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol (2012) 1.90
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell (2013) 1.86
Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis (2006) 1.85
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood (2006) 1.83
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med (2007) 1.82
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A (2005) 1.80
Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol (2005) 1.78
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood (2011) 1.77
Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol (2009) 1.76
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep (2002) 1.71